Posted by Michael Wonder on 17 Apr 2023
FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation
17 April 2023 - Today, the US FDA approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy to quicken the recovery of neutrophils in the body and reduce the risk of infection.
The product is intended for use in adults and paediatric patients 12 years and older with blood cancers planned for umbilical cord blood transplantation following a myeloablative conditioning regimen (treatment such as radiation or chemotherapy).
